Clinical Trial

The Effect of Low Frequency Soundwave Stimulation on Chemotherapy Induced Peripheral Neuropathy

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 23, 2026 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to assess the efficacy of SensoniQ® Treatment Station in preventing or reducing chemotherapy induced peripheral neuropathy symptoms (CIPNS) in patients receiving frontline carboplatin and paclitaxel chemotherapy for a gynecologic malignancy. This study will also assess the improvement of CIPNS in patients who have previously received carboplatin and paclitaxel therapy with persistent Grade 2 or worse neuropathy. The main questions this clinical trial aims to answer are: 1. To investigate the efficacy of SensoniQ® Treatment Station on the prevention or reduction of CIPNS in gynecologic oncology patients receiving front line carboplatin and paclitaxel. 2. To investigate the efficacy of SensoniQ® Treatment Station on the improvement of existing CIPNS in patients who previously received chemotherapy with platinum agent and paclitaxel for a gynecologic malignancy
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2023-07-31; most recent amendment 2026-03-19.
Status change: Recruiting → Active, Not Recruiting 2026-01-23
Status change: Not Yet Recruiting → Recruiting 2024-07-18
Trial Details
NCT Number NCT05980169
Lead Sponsor Augusta University
Conditions Gynecologic Cancer, Neuropathy;Peripheral
Enrollment 80 participants
Start Date 2023-11-29
Primary Completion 2026-06-01 (estimated)
Study Completion 2029-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-23